Development and internal validation of preoperative transition zone prostate cancer nomogram

Urology

Volumn 68, Issue 6, 2006, Pages 1295-1300

  Steuber, Thomas ^a   Chun, Felix K H ^b   Erbersdobler, Andreas ^a   Briganti, Alberto ^b   Haese, Alexander ^a   Graefen, Markus ^a   Schlomm, Thorsten ^a   Valiquette, Luc ^b   Huland, Hartwig ^a   Karakiewicz, Pierre I ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NOMOGRAM; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

ADULT; AGED; BIOPSY, NEEDLE; ENDOSONOGRAPHY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NOMOGRAMS; PREOPERATIVE CARE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 33845315563     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.08.1066     Document Type: Article

References (20)

1. McNeal J.E., Redwine E.A., Freiha F.S., et al. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 (1988) 897-906
2. Reissigl A., Pointner J., Strasser H., et al. Frequency and clinical significance of transition zone cancer in prostate cancer screening. Prostate 30 (1997) 130-135
3. Augustin H., Hammerer P.G., Blonski J., et al. Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy?. Urology 62 (2003) 79-85
4. Noguchi M., Stamey T.A., Neal J.E., et al. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 163 (2000) 1751-1755
5. Augustin H., Erbersdobler A., Hammerer P.G., et al. Prostate cancers in the transition zone: part 2-clinical aspects. BJU Int 94 (2004) 1226-1229
6. Grignon D.J., and Sakr W.A. Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland?. J Cell Biochem Suppl 19 (1994) 267-269
7. Greene D.R., Wheeler T.M., Egawa S., et al. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 146 (1991) 1069-1076
8. McNeal J.E. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 23 (1992) 258-266
9. Stamey T.A., Yemoto C.M., McNeal J.E., et al. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 163 (2000) 1155-1160
10. Stamey T.A., and Yemoto C.E. The clinical importance of separating transition zone (TZ) from peripheral zone (PZ) cancers. (abstract). J Urol 159 suppl (1998) 221
11. Stamey T.A., Sozen T.S., Yemoto C.M., et al. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol 159 (1998) 2009-2012
12. Shannon B.A., McNeal J.E., and Cohen R.J. Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behaviour. Pathology 35 (2003) 467-471
13. Steuber T., Karakiewicz P.I., Augustin H., et al. Transition zone cancers undermine the predictive accuracy of Partin table stage predictions. J Urol 173 (2005) 737-741
14. Augustin H., Erbersdobler A., Graefen M., et al. Differences in biopsy features between prostate cancers located in the transition and peripheral zone. BJU Int 91 (2003) 477-481
15. Stamey T.A., McNeal J.E., Yemoto C.M., et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 281 (1999) 1395-1400
16. Noguchi M., Stamey T.A., McNeal J.E., et al. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. J Urol 164 (2000) 1596-1600
17. Graefen M., Ohori M., Karakiewicz P.I., et al. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol 171 (2004) 200-203
18. Augustin H., Eggert T., Wenske S., et al. Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. J Urol 171 (2004) 177-181
19. Kattan M.W., Shariat S.F., Andrews B., et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 21 (2003) 3573-3579
20. Steuber T., Vickers A.J., Haese A., et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer 118 (2006) 1234-1240